A Pilot Study of the Safety and Immunogenicity of Folate Receptor Alpha Peptide-Loaded Dendritic Cell Vaccination in Patients With Advanced Stage Epithelial Ovarian Cancer
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 06 Aug 2019
Price : $35 *
At a glance
- Drugs TPIV 200 (Primary)
- Indications Adenocarcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions
- 15 Feb 2019 Planned End Date changed from 1 Dec 2018 to 1 Dec 2019.
- 15 Nov 2018 Planned End Date changed from 1 Sep 2018 to 1 Dec 2018.
- 31 Aug 2018 Biomarkers information updated